Qiagen Life Sciences
ASPR's IBx Portfolio
Product: Testing Reagents
Description of Project: : QIAGEN Beverly, Inc. was contracted to expand manufacturing capacity of enzymatic reagents and reagent kits used in COVID-19 molecular diagnostic tests.
Unique Impact: Molecular laboratory-based tests are essential for COVID-19 testing and diagnostics. The reagents QIAGEN produces are used to detect SARS-CoV-2 in collected samples and require highly controlled, validated, and regulatory-compliant manufacturing processes and facilities. This industrial base expansion effort will allow QIAGEN to increase its monthly production of reagent kits by 7,000 and enzymes by 5,100 milligrams by the end of February 2022 to support domestic laboratory testing for COVID-19.
Base Award Amount: $3,415,000.00
Category: Testing Capacity and Raw Materials